Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency (PID) in adults and children. Patients encounter recurrent viral and bacterial infections of the respiratory and gastrointestinal tract caused by ineffective pathogen clearance through strongly diminished immunoglobulin levels. [1] [2] [3] [4] Novel PID-associated genetic defects are now identified more rapidly through next-generation sequencing techniques. 5, 6 However, in case of CVID, monogenetic causes of disease are not identified in the vast majority of patients. 7, 8 In addition to B-cell differentiation and maturation disturbances (low class-switched memory B-cell numbers), patients with CVID can also exhibit aberrations within the T-cell compartment. 4, [7] [8] [9] Typically, these patients have low circulating T-cell numbers, relative CD8 T-cell expansion caused by diminished CD4 T-cell numbers, and low numbers of CD4 naive T cells. Several early T-cell signaling gene mutations have been described in patients with PIDs, which can be (in)directly linked to F-actin remodeling, which is essential for immune synapse (IS) formation. 10 Protein defects in Vav1 and z chain-associated protein of 70 kDa are examples of T-cell early signaling genes that associate with CVID disorders in which the hampered T-cell receptor (TCR) activation and strongly diminished F-actin remodeling results in defective IS formation. 9, 11 We identified 2 novel proline-serine-threonine phosphatase interacting protein 1 (PSTPIP1) mutations, a threonine to methionine substitution at amino acid 274 (T274M) and an arginine to cysteine substitution at amino acid 228 (R228C), in 2 patients with CVID and T-cell differentiation disturbances. The patient with the R228C mutation expressed defective memory CD4 T-cell differentiation and the patient with the T274M mutation had few CD4 T cells overall but a relative expansion In this study we addressed the role of PSTPIP1 in F-actin remodeling and IS stability through study of 2 patients with CVID in whom the T274M and R228C PSTPIP1 variants were found. To this end, we performed functional experiments with primary T cells and cell lines transfected with PSTPIP1 wild-type (WT), T274M, and R228C gene variants. We demonstrate in the primary patients' CD4 T cells that the T274M PSTPIP1 variant derails activation-induced F-actin polymerization contributed by preexisting nucleation for F-actin filaments. Furthermore, CD4 T cells from the patient with the T274M mutation were hyporesponsive to TCR activation, as shown by reduced induction of cytosolic calcium mobilization and F-actin recruitment to the IS. Overall, our findings support that PSTPIP1 mutations can underlie T-cell defects in patients with CVID, expanding the phenotype beyond PAPA and FMF syndromes.
METHODS

Patient samples
Patients provided written informed consent to participate in this study, which was approved by the Medical Ethical Committee of the UMC Utrecht. PBMCs were isolated from whole blood by using a standardized Ficoll procedure. CD4
1 T cells were enriched by using a CD4 1 T lymphocyte enrichment cocktail (BD, Franklin Lakes, NJ) and streptavadin beads, according to the manufacturer's protocol.
Flow cytometry
For F-actin quantification, primary CD4 T cells were fixed and permeabilized (FixPerm BD) at several time points (0, 2, 5, and 10 minutes) after anti-CD2 stimulation with CD2 TII2 and TII3 antibodies at a 1:100 dilution (kindly provided by Dr E. Reinherz, Dana Farber Institute, Boston, Mass) and anti-CD3 stimulation (OKT3 clone; eBioscience, San Diego, Calif). On fixation, cells were stained with phalloidin-fluorescein isothiocyanate (FITC) at a 50 mg/mL dilution (Enzo Life Sciences, Farmingdale, NY) in permeabilization buffer (BD) for 20 minutes at 48C, washed, and immediately acquired by using flow cytometry (FACSCanto II, BD).
Cytosolic calcium mobilization
PBMCs from the patient were stained with anti-CD3, anti-CD4, and anti-CD45RA/RO antibodies in RPMI 1640 medium without phenol red. Fluo-3 AM (5 mmol/L) and Fura-Red (10 mmol/L; Thermo Fisher Scientific, Waltham, Mass) were used as calcium indicators to visualize cytosolic calcium increase. Calcium dyes were incubated at 378C for 30 minutes, and for the last 10 minutes, specific antibodies were added. Cells were washed and resuspended in calcium-containing Hanks balanced salt solution (Thermo Fisher Scientific), with 10% FCS added. Calcium mobilization was acquired with flow cytometry; anti-CD3 was cross-linked with 20 mg/mL of a goat antimouse IgG antibody (Jackson ImmunoResearch, West Grove, Pa) to induce calcium flux.
Site-directed mutagenesis
Mutated PSTPIP1 was generated by using site-specific mutagenesis of WT PSTPIP1. The vector EX-T2966-M68 (GeneCopoeia, Rockville, Md) was grown in DH5a to obtain methylated DNA, and cDNA was purified with Maxiprep (Macherey-Nagel, D€ uren, Germany), according to the manufacturer's instructions. PSTPIP1 variants were entered by using a PCR reaction, according to the guidelines of Phusion DNA polymerase (F-5302S; Finnzymes, Thermo Fisher Scientific) with primers. Template (methylated) DNA was degraded by adding 1 mL of DpnI (R0176s; New England Biolabs, Ipswich, Mass) and incubated overnight at 378C. WT and mutant vectors were transformed in commercial DH5a (C2987I; New England Biolabs), and cDNA was purified. The PSTPIP1 variants were confirmed by means of sequencing.
Transfection
Jurkat cells were electroporated at 250 V and 975 mF (Genepulser II; BioRad Laboratories, Hercules, Calif) with an EX-T2966-M68 vector (GeneCopoeia) containing human HA-tagged (N-terminus) WT PSTPIP1, T274M-or R228C-mutated PSTPIP1, and flag-tagged CD2 (C-terminus). HEK293T cells were transfected with the same vectors by using FuGENE HD Transfection Reagent (Promega, Madison, Wis), according to the manufacturer's instructions.
Immunoprecipitation
HEK293T cells transfected with WT, T274M, or R228C PSTPIP1-HA and CD2-flag and cultured in Dulbecco modified Eagle medium supplemented with 10% FCS. Approximately 1½ days after transfection, cells were harvested, resuspended in PBS, and stimulated with anti-CD2 antibodies and kept on ice directly after 2 minutes of stimulation. Subsequently, cells were lysed in a standardized immunoprecipitation buffer with 1% Triton and 1% protease inhibitor (HALT; Thermo Fisher Scientific), and CD2-flag pulldown was performed with FLAG-conjugated beads (Sigma, St Louis, Mo). Lysates were subjected to SDS-PAGE and Western blotting for CD2-flag (monoclonal anti-FLAG M2-peroxidase; Sigma-Aldrich) and PSTPIP1-HA (mouse IgG2bk anti-HA 12CA5) and horseradish peroxidase-conjugated donkey anti-mouse IgG light chain-specific antibody (Jackson ImmunoResearch).
Confocal imaging
Jurkat cells were transfected with WT, T274M, or R228C PSTPIP1-HA and kept in RPMI 1640 medium supplemented with 10% FCS. After 2 days, cells were adhered to poly-L-lysine-coated confocal chambers and stimulated with anti-CD3/CD28 beads for 10 minutes. After stimulation, cells were kept on ice and fixed/permeabilized with Fixation/Permeabilization Solution (BD) for 30 minutes. After fixation, cells were stained with 5 mg/mL phalloidin-FITC (1:200 dilution; Enzo Life Sciences) and washed with permeabilization buffer (BD). J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 6 For imaging of HEK293T cells transfected with WT, T274M, or R228C PSTPIP1-HA and CD2-flag, cells were permeabilized in Triton 0.1%, blocked with 5% BSA, and washed in PBS with Tween 0.5%. Cells were stained with monoclonal FLAG M2-FITC (1:200) and mouse IgG2bk anti-HA 12CA5 (both from Sigma-Aldrich) and after block with goat serum with goat antimouse Alexa Fluor 647. Acquisition was performed on a Zeiss LSM710 confocal microscope (Zeiss, Oberkochen, Germany). Images were obtained with a 1.33 optical zoom using the Plan-Apochromat 633 1.40 oil differential interference contrast M27 objective (Zeiss) and processed with Zen 2009 software (Zeiss Enhanced Navigation).
RESULTS
Two patients with CVID with novel PSTPIP1 mutations
Patient 1, with the R228C mutation, presented with recurrent respiratory tract infections complicated by bronchiectasis, severe enteropathy, and an unclassified skin rash. Laboratory screening revealed low IgG, IgA, and IgM levels (<22 SD); absent specific anti-pneumococcal serotype IgG responses; and initially diminished memory B-cell percentages, although normalizing over time (Fig 1, A) . Patient 2, with the T274M mutation, presented with recurrent viral and bacterial infections of the respiratory tract, low IgG and IgA levels (<22 SD), and absent specific responses to pneumococcal serotypes. Memory B-cell percentages were consistently disturbed (no detected IgA memory B cells and IgG memory B cells of 0.2%; Fig 1, A) . Fig 1, A) while overrepresenting the central memory T-cell subset (Fig 1, B) .
Based on clinical and laboratory findings, both patients were given a diagnosis of CVID and treated with immunoglobulin substitution therapy. 22 Through next-generation sequencing, 5 patient 1 was found to have the heterozygous mutation c.682C>T in the PSTPIP1 gene, resulting in a R228C amino acid substitution and healthy control subjects (HCs) stimulated with anti-CD2 and anti-CD3 antibodies. B, Baseline F-actin percentages of patients with the R228C and T274M PSTPIP1 mutations relative to HC baseline F-actin content. C, F-actin content increase in the patient with the R228C mutation (n 5 2), the patient with the T274M mutation (n 5 2), and HCs (n 5 8) on anti-CD2 and anti-CD3 stimulation relative to baseline F-actin levels (as depicted in Fig 2, B) of the individual patients and HCs. Areas under the curve (AUCs) were calculated as the sum of F-actin increases over time points of 0, 2, 5, and 10 minutes per subject (HCs and patients). D, Baseline F-actin percentages of B cells from the patients with the R228C and T274M PSTPIP1 mutations (n 5 1) relative to HCs (n 5 3).
in the coiled-coil region of the PSTPIP1 protein. Patient 2 had a heterozygous mutation at c.821C>T, resulting in a T274M amino acid substitution (Fig 1, D and E) . Both mutations were predicted to be pathogenic and were not, or only 3 times detected in control populations (ExAC database, Broad Institute), highly conserved amino acid residues, and substantial physiochemical differences between amino acid residues. For both patients, the fathers were also carrying the mutations (Fig 1, C) . In case of the R228C variant, the father had diminished immunoglobulin levels and acne. For the T274M variant, the father was not screened further because of unavailability. The sister of the patient with the T274M mutation is currently experiencing immunodeficiency symptoms. PSTPIP1 mutations have been shown to be causative of PAPA syndrome. 20, 23 Our patients did not have any PAPA syndrome characteristics; in addition, serum IL-1b levels were not increased (data not shown), and LPS stimulation of PBMCs did not trigger increased IL-1b levels (Fig 1, F) . 17 Finally, considering that PSTPIP1 binds WASP, 12 we stained for WASP protein in T cells of the patient with the R228C mutation and healthy control subject (patients' cells from the patient with the PSTPIP1 T274M mutation; cells were unfortunately unavailable). No significant changes were seen (Fig 1, G) , which is expected because PSTPIP1 binds to WASP through its SH3 domain, 12 which was unscathed by the T274M mutation. Thus we concluded that the PSTPIP1 mutations, as found in our patients, did not result in typical PAPA syndrome but might contribute to immunodeficiency.
Defective activation-induced F-actin polymerization of CD4 T cells from the patient with the T274M PSTPIP1 mutation
On TCR and CD2 ligation, PSTPIP1 recruitment serves to scaffold the interaction between CD2, PTP-PEST, and WASP, the latter protein driving F-actin polymerization. PTP-PEST downregulates TCR/CD2 signaling and WASP activation through dephosphorylation of PSTPIP1, thus keeping the F-actin modulation and IS formation under tight control. 14, 16, 21, 23 We first addressed whether PSTPIP1 can control T-cell activation.
We stimulated primary CD4 T cells of both patients using anti-CD2 and anti-CD3 antibodies and cross-linking with goat antimouse IgG fragments for 0, 2, 5, and 10 minutes. Subsequently, F-actin polymerization was visualized through staining with phalloidin-FITC and quantified by using flow cytometry. 12 We found that unstimulated T cells from the patient with the T274M mutation already displayed polymerized F-actin, whereas healthy control CD4 T cells did not (Fig 2, A and B) . The CD4 T cells of the patient with the T274M mutation were hyporesponsive to anti-CD2 stimulation, with a significantly lower area under the curve when compared with healthy age-matched control subjects (Fig 2, C) . Stimulation of CD4 1 T cells from the patient with the T274M mutation with anti-CD3 resulted in a steady increase of F-actin content over time (Fig 2, A and B) , as opposed to T cells from the healthy control subjects and the patient with the R228C mutation, which showed a decrease in F-actin content after 10 minutes. Thus especially the CD4 1 T cells from the patient with the T274M mutation show a preactivated status of F-actin, which derails T-cell activation-induced cytoskeletal remodeling. Corresponding to the pre-existing hyperactivated state of T cells from the patient with the T274M mutation, the F-actin content of resting B cells from the patient with the T274M mutation was also increased when compared with healthy control subjects, whereas B cells from the patient with the R228C mutation had less baseline levels of F-actin (Fig 2, D) .
We continued our PSTPIP1 primary T-cell studies comparing T cells from the patient with the T274M mutation with T cells from healthy control subjects and patients with CVID because of the J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 6 more striking phenotype observed in the patient with the T274M mutation. We addressed cytosolic calcium mobilization of CD4 memory and naive T cells from the primary patients and healthy control subjects, as triggered by cross-linking of CD3 with anti-CD3 and goat anti-mouse IgG fragments. Baseline calcium levels were much increased in CD4 T cells from the patient with the T274M mutation compared with those from patients with CVID with normal or altered CD4 T-cell differentiation (Fig 3, A) , which is again suggestive of a preactivated state. Activation-induced calcium mobilization of T cells from the patient with the T274M mutation was low when compared with either T cells from healthy control subjects or patients with CVID with T-cell differentiation defects (low CD4 naive T-cell percentages; Fig 3, B) . Separate analysis of naive and memory T-cell calcium flux (CD4CD45RA 1 and CD4CD45RO 1 ) revealed that especially the memory subset of CD4 T cells from the patient with the T274M mutation were less responsive than their cellular counterparts from patients with CVID with altered T-cell differentiation (Fig 3, B) . However, the TCR CDR3 repertoire did not differ significantly from healthy control subjects in contrast to what has been described in T cells from patients with CVID (our unpublished data). 24, 25 Considering that controlled F-actin polymerization is pivotal to cell motility, 26, 27 we investigated T-cell migration of primary CD4 T cells of the patient with the T274M mutation and healthy control subjects. To this end, we enriched CD4 T cells from the patient with the T274M mutation (n 5 2) and those from healthy control subjects (n 5 5). We tracked the motility of CD4 T cells through the collagen matrix using time-lapse light microscopy (2 images per minute for 4 hours). We found that in comparison with CD4 T cells from healthy control subjects, CD4 T cells from the patient with the T274M mutation displayed faster motility without prior stimulation (Fig 3, C) . Thus the increased level of ready-made F-actin polymers in resting CD4 T cells from the patient with the T274M PSTPIP1 mutation translates to increased F-actin-mediated motility. The pre-existence of F-actin filament nucleation can contribute to the observed shortfall of CD4 T cells from the patient with the T274M mutation to respond to TCR and anti-CD2 triggering-induced activation.
Loss of CD2 foci in activated transfected HEK293T cells from the patient with the T274M PSTPIP1 mutation PSTPIP1 in resting cells is distributed in the cytosol and available to be recruited to surface-expressed CD2 on triggering of the TCR and coreceptors. 13 Especially for unstimulated T cells from the patient with the T274M PSTPIP1 mutation, we observed ready-made F-actin polymers and defective control of anti-CD2 activation-induced F-actin polymerization. These data prompted us to address the binding between CD2 and PSTPIP1. Therefore we transfected HEK293T cells with expression plasmids encoding HA-tagged versions of WT, R228C, and T274M PSTPIP1 together with a flag-tagged CD2 expression plasmid; transfection efficiencies were always 60% to 80%. We generated cell lysates using 1% Triton X-100 detergent, and from these lysates, we performed pulldown of CD2-flag with anti-flag-conjugated agarose beads. In CD2-flag pulldown fractions, we measured the amount of CD2-associated PSTPIP1 variants under both unstimulated and anti-CD2-stimulated (2 minutes) conditions. We found that CD2 stimulation stimulates PSTPIP1 binding to CD2, although prebound PSTPIP1 is already present, at least in our cell lysatebased experimental setup. Particularly in T cells from the patient with the T274M mutation, more PSTPIP1 appeared prebound to CD2, although data did not reach significance (n 5 3; Fig 4, A) .
We next addressed membrane remodeling using live-cell confocal microscopy. CD2 stimulation caused CD2 clustering in WT PSTPIP1, confirming earlier data. 13 In transfectants from the patient with the T274M PSTPIP1 mutation, CD2 remained distributed in scattered fashion throughout the cellular J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 6 membranes, and in transfectants from the patient with the R228C PSTPIP1 mutation, an intermediate phenotype was seen (Fig 4,  B) . Cross-sectional analyses support these notions, with higher PSTPIP1 signals colocalizing with the CD2 signal in the T274M PSTPIP1 variant. These data support a role for PSTPIP1 as a scaffold protein that connects CD2 to F-actin polymerization, as mediated by WASP. 12, 28 Defective immune synapse formation in T cells from the patient with the T274M PSTPIP1 mutation Finally, we investigated a possible role for PSTPIP1 in IS formation. Jurkat T cells were transfected with plasmids encoding the WT, T274M, and R228C PSTPIP1 variants; incubated with anti-CD3/CD28 beads (10 minutes); and subsequently fixed, permeabilized, and stained with phalloidin-FITC. Confirming the increased baseline F-actin content of the patient, without stimulation, transfected Jurkat cells from the patient with the T274M PSTPIP1 mutation already expressed increased phalloidin-FITC fluorescence (Fig 5, A and B) .
We next visualized the specific recruitment of F-actin toward the bead contact site and quantified images by using ImageJ software (National Institutes of Health, Bethesda, Md). Jurkat T cells overexpressing the R228C variant showed intermediately reduced F-actin recruitment to the anti-CD3/CD28 bead, whereas the T274M PSTPIP1-overexpressing Jurkat T cells showed much reduced F-actin recruited to the beads (Fig 5, B and C) . Thus PSTPIP1 controls IS formation, which had already been shown to be an F-actin-dependent process. 29, 30 Considering that the 2 patients expressing R228C and T274M PSTPIP1 mutations demonstrated T-and B-cell immunodeficiency, the F-actin polymerization defects observed might contribute to the clinical phenotypes observed.
DISCUSSION
Here we describe 2 novel PSTPIP1 mutations, R228C and T274M, in 2 patients with CVID presenting with aberrant T-cell compartments but with no classical PAPA or FMF syndrome characteristics. Specifically, we found that resting CD4 T cells from the patient with the T274M mutation were in a preactivated state and were subsequently less responsive to T-cell activation. We argue that the latter might relate to the pre-existing nucleation for F-actin filaments.
In this study we focused primarily on the patients' T-cell compartments, elaborating on earlier T-cell model-based PSTPIP1 research. 12, 13 To our knowledge, we are the first to report how PSTPIP1 mutations can contribute to PIDs by showing how PSTPIP1 mutations modulate early signaling events in primary CD4 T cells. T cells showed defects in stimulationinduced F-actin polymerization and failure to create sustained calcium flux. T-cell unresponsiveness was especially evident in CD4 memory T cells, displaying diminished cytosolic calcium mobilization on TCR triggering onward from an increased baseline calcium level. Of note, in healthy conditions naive T cells mobilize relatively more calcium on TCR-specific triggering than memory T cells (own unpublished data). 31 The severe reduction in calcium mobilization of CD4 memory T cells of the patient with the T274M mutation might relate to the altered composition of the T-cell memory compartment consequent to lymphopeniainduced homeostatic memory cell proliferation, although further investigation is beyond the scope of this study.
We next looked into cell migration of primary CD4 T cells from the patients and healthy donor control subjects without prior stimulation. CD4 T cells of healthy control subjects (n 5 5) migrated at a median velocity of 3 mm/min, as reported earlier for similar collagen densities (1.7 mg/mL). 32 T-cell velocity in the patient with the T274M mutation approached 4 mm/min instead. Because T cells rely on intact actin dynamics for their motility, the increase in F-actin polymers in resting T cells from the patient with the T274M mutation likely contributes to increased motility. On the contrary, an increase in F-actin polymers in T274M PSTPIP1-expressing cells was associated with defective IS formation. Thus the greater F-actin content at baseline facilitates enhanced T-cell motility but probably ineffective adhesion once an antigen would be encountered because CD2-mediated F-actin polymerization is hampered.
A limitation of our study is the paucity of functional B-cell experiments. Both patients were incapable of generating normal memory class-switched B-cell numbers (combined <2% of total B-cell population), limiting our ability for functional B-cell assays. The patients had absent anti-pneumococcal serotype responses. We propose that the aberrant F-action polymerization and signaling of CD4 T cells in the patient with the T274M PSTPIP1 mutation might similarly cause unstable ISs between CD4 T-follicular helper cells and B cells for abolishment of T-cell help, as needed for B-cell differentiation and memory classswitching. Of note, also B cells from the patient with the T274M PSTPIP1 mutation expressed increased baseline F-actin levels, supporting that PSTPIP1 might also control B-cell activation and function. However, PSTPIP1 is expressed in B cells at lower levels than in T cells. 13 Lack of sufficient patients' B cells, absence of pre-existing research on PSTPIP1-associated surface proteins in B cells, and a good model to study PSTPIP1 functioning in B cells precluded further research at this time.
In conclusion, our data support a role for PSTPIP1 mutations in immunodeficiency, expanding the PSTPIP1 phenotype beyond inflammasome-mediated disorders, such as PAPA syndrome. Here we show a role for PSTPIP1 that revealed itself in patients with CVID by contribution to T-cell deficiency through altered F-actin polymerization. Further studies on PSTPIP1 to elucidate the mechanisms of PSTPIP1 in patients with antibody deficiencies are warranted.
Clinical implications: Pathogenic PSTPIP1 mutations can be found in patients with CVID and likely contribute to altered T-cell phenotypes in these patients.
